Breaking News

CorePharma Adds Two Facilities, Expands CDMO Capabilities

Both facilities will be operational in Q3 2024.

Author Image

By: Charlie Sternberg

Associate Editor

CorePharma is expanding its development and manufacturing capacities with the incorporation of two new cGMP facilities, showcasing the NJ-based company’s rapid growth in the CDMO sector. About the New cGMP Facilities A 20,000 ft2 Research and Development facility with Analytical, Development and Pilot Scale cGMP manufacturing capabilities located on its current campus in Middlesex, NJ will enable CorePharma to provide partners with accelerated solutions for their development and clini...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters